EA038993B1 - Человеческие антитела к гликопротеину вируса эбола - Google Patents
Человеческие антитела к гликопротеину вируса эбола Download PDFInfo
- Publication number
- EA038993B1 EA038993B1 EA201791675A EA201791675A EA038993B1 EA 038993 B1 EA038993 B1 EA 038993B1 EA 201791675 A EA201791675 A EA 201791675A EA 201791675 A EA201791675 A EA 201791675A EA 038993 B1 EA038993 B1 EA 038993B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107581P | 2015-01-26 | 2015-01-26 | |
| US62/107,581 | 2015-01-26 | ||
| US201562161356P | 2015-05-14 | 2015-05-14 | |
| US62/161,356 | 2015-05-14 | ||
| US201562245703P | 2015-10-23 | 2015-10-23 | |
| US62/245,703 | 2015-10-23 | ||
| PCT/US2016/014720 WO2016123019A1 (en) | 2015-01-26 | 2016-01-25 | Human antibodies to ebola virus glycoprotein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201791675A1 EA201791675A1 (ru) | 2017-12-29 |
| EA038993B1 true EA038993B1 (ru) | 2021-11-18 |
Family
ID=55300806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791675A EA038993B1 (ru) | 2015-01-26 | 2016-01-25 | Человеческие антитела к гликопротеину вируса эбола |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9771414B2 (enExample) |
| EP (2) | EP4653051A3 (enExample) |
| JP (4) | JP6829199B2 (enExample) |
| KR (1) | KR102641731B1 (enExample) |
| CN (2) | CN113354732B (enExample) |
| AU (2) | AU2016211783B2 (enExample) |
| BR (1) | BR112017015845A2 (enExample) |
| CA (1) | CA2974899A1 (enExample) |
| CL (3) | CL2017001920A1 (enExample) |
| CO (1) | CO2017007619A2 (enExample) |
| DK (1) | DK3250591T3 (enExample) |
| EA (1) | EA038993B1 (enExample) |
| ES (1) | ES3054263T3 (enExample) |
| FI (1) | FI3250591T3 (enExample) |
| HR (1) | HRP20251642T1 (enExample) |
| IL (1) | IL253358B (enExample) |
| LT (1) | LT3250591T (enExample) |
| MA (1) | MA41421B1 (enExample) |
| MD (1) | MD3250591T2 (enExample) |
| MX (2) | MX392533B (enExample) |
| MY (4) | MY208081A (enExample) |
| PH (1) | PH12017501277B1 (enExample) |
| PL (1) | PL3250591T3 (enExample) |
| PT (1) | PT3250591T (enExample) |
| RS (1) | RS67563B1 (enExample) |
| SG (2) | SG10202007835QA (enExample) |
| SI (1) | SI3250591T1 (enExample) |
| SM (1) | SMT202500454T1 (enExample) |
| TW (1) | TWI710573B (enExample) |
| UY (1) | UY36538A (enExample) |
| WO (1) | WO2016123019A1 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| ES2655051T3 (es) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| CN109477074B (zh) | 2016-02-19 | 2023-01-24 | 威斯康星旧生研究基金会 | 用于疫苗开发的改进的乙型流感病毒复制 |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| US20200148750A1 (en) | 2016-07-21 | 2020-05-14 | Emory University | Ebola Virus Antibodies and Binding Agents Derived Therefrom |
| KR20230041834A (ko) | 2016-08-16 | 2023-03-24 | 리제너론 파아마슈티컬스, 인크. | 혼합물로부터 개별 항체들을 정량하는 방법 |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| CN119492842A (zh) | 2016-10-25 | 2025-02-21 | 里珍纳龙药品有限公司 | 用于色谱数据分析的方法和系统 |
| CN113512111B (zh) * | 2017-03-10 | 2023-08-15 | 北京天广实生物技术股份有限公司 | 抗埃博拉病毒单克隆抗体、其制备方法及用途 |
| BR112020000127A2 (pt) | 2017-07-06 | 2020-07-07 | Regeneron Pharmaceuticals, Inc. | método para selecionar um hidrolisado de soja, e, glicoproteína |
| US12162925B2 (en) * | 2017-09-15 | 2024-12-10 | The Wistar Institute Of Anatomy And Biology | DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein |
| CN118416215A (zh) | 2017-09-19 | 2024-08-02 | 里珍纳龙药品有限公司 | 减少粒子形成的方法以及由其形成的组合物 |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| BR112020010615A2 (pt) | 2017-12-22 | 2020-10-27 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema |
| RU2686630C1 (ru) * | 2017-12-22 | 2019-04-29 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Штаммы гибридных клеток животных Mus. Musculus - продуценты моноклональных антител к белку GP вируса Эбола (subtype Zaire) и моноклональные антитела к белку GP вируса Эбола (subtype Zaire) |
| EP3724223A1 (en) * | 2018-01-02 | 2020-10-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| MX2020008095A (es) | 2018-01-31 | 2020-09-24 | Regeneron Pharma | Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos. |
| WO2019152607A1 (en) * | 2018-01-31 | 2019-08-08 | The Wistar Institute Of Anatomy And Biology | Nucleic acid antibody constructs for use against ebola virus |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| KR20200127979A (ko) | 2018-02-28 | 2020-11-11 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 오염물질을 확인하기 위한 시스템 및 방법 |
| CN108373500A (zh) * | 2018-03-12 | 2018-08-07 | 中国科学院微生物研究所 | 一种热稳定性埃博拉治疗性抗体的制备及应用 |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CA3246952A1 (en) | 2018-03-19 | 2025-10-31 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| WO2019190931A1 (en) * | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Anti-pfrh5 antibodies and antigen-binding fragments thereof |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| WO2020014443A1 (en) * | 2018-07-12 | 2020-01-16 | Vanderbilt University | Pan-ebolavirus neutralizing human antibodies and methods of use therefor |
| JP7783047B2 (ja) | 2018-08-07 | 2025-12-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| EP3840780A1 (en) | 2018-08-20 | 2021-06-30 | Wisconsin Alumni Research Foundation | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| US11754569B2 (en) | 2018-08-30 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| CN111138527B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用 |
| CN111138526B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 一种抗埃博拉病毒糖蛋白gp2亚基的单克隆抗体2g1及应用 |
| CN111138531B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 特异结合于ebov的gp1亚基的单克隆抗体8f9及应用 |
| CN111138528B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 特异性结合于埃博拉病毒糖蛋白聚糖帽的单克隆抗体5a8 |
| PL3857237T3 (pl) | 2019-01-16 | 2023-07-10 | Regeneron Pharmaceuticals, Inc. | Sposoby charakteryzowania mostka disiarczkowego |
| WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| EP3934620A1 (en) | 2019-03-05 | 2022-01-12 | Regeneron Pharmaceuticals, Inc. | Human serum albumin in formulations |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| AU2020275406A1 (en) | 2019-05-13 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| JP7627911B2 (ja) | 2019-08-27 | 2025-02-07 | ウィスコンシン アルムニ リサーチ ファンデイション | 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| JP6761889B1 (ja) | 2019-11-11 | 2020-09-30 | 株式会社Ｇｓｐエンタープライズ | 抗ヒトＣｒｉｐｔｏ−１抗体 |
| MY207613A (en) | 2019-11-25 | 2025-03-06 | Regeneron Pharma | Sustained release formulations using non-aqueous emulsions |
| GB201917480D0 (en) * | 2019-11-29 | 2020-01-15 | Univ Oxford Innovation Ltd | Antibodies |
| US11835527B2 (en) | 2020-01-21 | 2023-12-05 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| EP4093415A1 (en) | 2020-01-24 | 2022-11-30 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized na |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CN115243718A (zh) | 2020-01-24 | 2022-10-25 | 瑞泽恩制药公司 | 稳定的抗体制剂 |
| WO2021173753A1 (en) | 2020-02-26 | 2021-09-02 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| US12605459B2 (en) | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| IL300828A (en) | 2020-08-31 | 2023-04-01 | Regeneron Pharma | Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants |
| WO2022074630A1 (en) * | 2020-10-09 | 2022-04-14 | Auxilla Pharmaceuticals And Research Llp | Liquid oral suspension of favipiravir |
| MX2023006077A (es) | 2020-11-25 | 2023-06-06 | Regeneron Pharma | Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa. |
| US12350374B2 (en) | 2020-12-17 | 2025-07-08 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| EP4274608A4 (en) * | 2021-01-05 | 2025-07-09 | Immunome Inc | ANTIBODY COCKTAIL AGAINST SARS-CoV-2 SPIKE PROTEIN |
| TW202233827A (zh) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | 改良細胞培養中蛋白質效價的方法 |
| AR125585A1 (es) | 2021-03-03 | 2023-08-02 | Regeneron Pharma | Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas |
| BR112023024984A2 (pt) | 2021-06-01 | 2024-02-20 | Regeneron Pharma | Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
| JP2024538673A (ja) | 2021-10-07 | 2024-10-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ｐＨモデリング及び制御のシステム及び方法 |
| KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
| MX2024005090A (es) | 2021-10-26 | 2024-07-19 | Regeneron Pharma | Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas. |
| CA3242639A1 (en) | 2022-01-14 | 2023-07-20 | Regeneron Pharmaceuticals, Inc. | Verrucarin A derivatives and their antibody-drug conjugates |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| WO2024163708A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| CN121925272A (zh) | 2023-09-29 | 2026-04-24 | 瑞泽恩制药公司 | 利用受控成核进行冻干 |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| AU2024373307A1 (en) | 2023-11-02 | 2026-05-14 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
| CN120943942A (zh) * | 2024-09-12 | 2025-11-14 | 南京诺唯赞生物科技股份有限公司 | 特异性结合hpv的抗体 |
| WO2026060350A1 (en) | 2024-09-13 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods |
| WO2026076201A2 (en) | 2024-10-03 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools |
| WO2026080597A1 (en) | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
| CN119462912B (zh) * | 2025-01-15 | 2025-08-19 | 中国人民解放军军事科学院军事医学研究院 | 抗埃博拉病毒vp40蛋白的纳米抗体及在病毒检测中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004018649A2 (en) * | 2002-08-23 | 2004-03-04 | United States Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein |
| WO2009094755A1 (en) * | 2008-02-01 | 2009-08-06 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Monoclonal antibodies for ebola and marburg viruses |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7089600A (en) | 1999-08-30 | 2001-03-26 | U.S. Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| CA2741523C (en) | 2008-10-24 | 2022-06-21 | Jonathan S. Towner | Human ebola virus species and compositions and methods thereof |
| US8409838B2 (en) | 2009-06-02 | 2013-04-02 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
| LT2975051T (lt) | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| WO2011071574A2 (en) | 2009-09-02 | 2011-06-16 | United States Deparment Of The Army, As Represented By The Secretary Of The Army | Monoclonal antibodies against glycoprotein of ebola sudan boniface virus |
| US9346875B2 (en) | 2013-06-03 | 2016-05-24 | Albert Einstein College Of Medicine, Inc. | Therapy for filovirus infection |
| KR20170047192A (ko) | 2014-02-19 | 2017-05-04 | 조디 베리 | 에볼라 단클론성 항체 |
| CN103864904B (zh) * | 2014-03-04 | 2016-01-20 | 中国人民解放军军事医学科学院生物工程研究所 | 基于埃博拉病毒包膜蛋白的抗原片段、截短体及应用 |
| US20170158753A1 (en) | 2014-06-25 | 2017-06-08 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
| US10435461B2 (en) | 2014-08-20 | 2019-10-08 | Albert Einstein College Of Medicine | Therapy for filovirus infection |
| SG10201902924RA (en) | 2014-10-03 | 2019-05-30 | Massachusetts Inst Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| WO2016061504A2 (en) | 2014-10-17 | 2016-04-21 | The University Of Chicago | Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein |
| TWI710573B (zh) * | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
-
2016
- 2016-01-22 TW TW105101967A patent/TWI710573B/zh active
- 2016-01-24 MA MA41421A patent/MA41421B1/fr unknown
- 2016-01-25 SM SM20250454T patent/SMT202500454T1/it unknown
- 2016-01-25 KR KR1020177021579A patent/KR102641731B1/ko active Active
- 2016-01-25 PL PL16703030.3T patent/PL3250591T3/pl unknown
- 2016-01-25 MX MX2017009716A patent/MX392533B/es unknown
- 2016-01-25 EP EP25206939.8A patent/EP4653051A3/en active Pending
- 2016-01-25 MY MYPI2023001378A patent/MY208081A/en unknown
- 2016-01-25 EP EP16703030.3A patent/EP3250591B1/en active Active
- 2016-01-25 PH PH1/2017/501277A patent/PH12017501277B1/en unknown
- 2016-01-25 MY MYPI2021007427A patent/MY196224A/en unknown
- 2016-01-25 BR BR112017015845-0A patent/BR112017015845A2/en active Search and Examination
- 2016-01-25 HR HRP20251642TT patent/HRP20251642T1/hr unknown
- 2016-01-25 SG SG10202007835QA patent/SG10202007835QA/en unknown
- 2016-01-25 EA EA201791675A patent/EA038993B1/ru unknown
- 2016-01-25 JP JP2017536549A patent/JP6829199B2/ja active Active
- 2016-01-25 MD MDE20170310T patent/MD3250591T2/ro unknown
- 2016-01-25 MY MYPI2017702504A patent/MY180045A/en unknown
- 2016-01-25 MY MYPI2019007583A patent/MY189452A/en unknown
- 2016-01-25 ES ES16703030T patent/ES3054263T3/es active Active
- 2016-01-25 WO PCT/US2016/014720 patent/WO2016123019A1/en not_active Ceased
- 2016-01-25 RS RS20251307A patent/RS67563B1/sr unknown
- 2016-01-25 US US15/005,334 patent/US9771414B2/en active Active
- 2016-01-25 CN CN202110499070.6A patent/CN113354732B/zh active Active
- 2016-01-25 SG SG11201705681YA patent/SG11201705681YA/en unknown
- 2016-01-25 PT PT167030303T patent/PT3250591T/pt unknown
- 2016-01-25 FI FIEP16703030.3T patent/FI3250591T3/fi active
- 2016-01-25 DK DK16703030.3T patent/DK3250591T3/da active
- 2016-01-25 LT LTEPPCT/US2016/014720T patent/LT3250591T/lt unknown
- 2016-01-25 SI SI201631929T patent/SI3250591T1/sl unknown
- 2016-01-25 CA CA2974899A patent/CA2974899A1/en active Pending
- 2016-01-25 AU AU2016211783A patent/AU2016211783B2/en active Active
- 2016-01-25 CN CN201680018389.XA patent/CN107667115B/zh active Active
- 2016-01-26 UY UY0001036538A patent/UY36538A/es active IP Right Grant
-
2017
- 2017-07-09 IL IL253358A patent/IL253358B/en unknown
- 2017-07-26 MX MX2021015687A patent/MX2021015687A/es unknown
- 2017-07-26 CL CL2017001920A patent/CL2017001920A1/es unknown
- 2017-07-27 CO CONC2017/0007619A patent/CO2017007619A2/es unknown
- 2017-08-28 US US15/688,474 patent/US10081670B2/en active Active
-
2018
- 2018-08-22 US US16/108,096 patent/US10501526B2/en active Active
-
2019
- 2019-10-24 US US16/663,261 patent/US10829544B2/en active Active
-
2020
- 2020-02-28 CL CL2020000498A patent/CL2020000498A1/es unknown
- 2020-05-07 JP JP2020081768A patent/JP7672200B2/ja active Active
- 2020-09-30 US US17/039,557 patent/US11530255B2/en active Active
-
2021
- 2021-05-05 AU AU2021202839A patent/AU2021202839A1/en not_active Abandoned
-
2022
- 2022-11-09 US US18/053,927 patent/US12152067B2/en active Active
- 2022-12-26 CL CL2022003763A patent/CL2022003763A1/es unknown
-
2023
- 2023-03-07 JP JP2023034449A patent/JP2023065648A/ja active Pending
-
2025
- 2025-02-10 JP JP2025019929A patent/JP7796918B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004018649A2 (en) * | 2002-08-23 | 2004-03-04 | United States Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein |
| WO2009094755A1 (en) * | 2008-02-01 | 2009-08-06 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Monoclonal antibodies for ebola and marburg viruses |
Non-Patent Citations (9)
| Title |
|---|
| "Recombinant Antibodies for Immunotherapy", 1 January 2009, CAMBRIDGE UNIVERSITY PRESS , GB , ISBN: 978-0-521-88732-8, article ANDREW MURPHY: "VelocImmune: Immunoglobulin Variable Region Humanized Mice", pages: 100 - 107, XP008160379, DOI: http://dx.doi.org/10.1017/CBO9780511596773.011 * |
| "The Protein Protocols Handbook", 1 January 1996, HUMANA PRESS , Totowa, NJ , ISBN: 9781603272599, article GLENN E. MORRIS: "Epitope Mapping of Protein Antigens by Competition ELISA", pages: 595 - 600, XP055007939, DOI: 10.1007/978-1-60327-259-9_96 * |
| L. N. SHINGAROVA, N. V. TIKUNOVA, T. E. YUN, A. A. CHEPURNOV, T. K. ALIEV, T. A. BATANOVA, E. F. BOLDYREVA, O. V. NEKRASOVA, V. A.: "Recombinant full-size human antibody to Ebola virus", RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, PLEIADES PUBLISHING, MOSCOW, vol. 33, no. 6, 1 November 2007 (2007-11-01), Moscow, pages 554 - 561, XP055260862, ISSN: 1068-1620, DOI: 10.1134/S1068162007060040 * |
| LONBERG, N.: "Fully human antibodies from transgenic mouse and phage display platforms", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD., GB, vol. 20, no. 4, 1 August 2008 (2008-08-01), GB , pages 450 - 459, XP025771204, ISSN: 0952-7915, DOI: 10.1016/j.coi.2008.06.004 * |
| MARUYAMA T, ET AL.: "Ebola Virus can be effectively neutralized by antibody produced in natural human infection", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 7, 1 July 1999 (1999-07-01), US , pages 6024 - 6030, XP002974707, ISSN: 0022-538X * |
| O. MARTINEZ, L. TANTRAL, N. MULHERKAR, K. CHANDRAN, C. F. BASLER: "Impact of Ebola Mucin-Like Domain on Antiglycoprotein Antibody Responses Induced by Ebola Virus-Like Particles", JOURNAL OF INFECTIOUS DISEASES, UNIVERSITY OF CHICAGO PRESS, US, vol. 204, no. suppl 3, 1 November 2011 (2011-11-01), US , pages S825 - S832, XP055238414, ISSN: 0022-1899, DOI: 10.1093/infdis/jir295 * |
| X. QIU, J. AUDET, G. WONG, S. PILLET, A. BELLO, T. CABRAL, J. E. STRONG, F. PLUMMER, C. R. CORBETT, J. B. ALIMONTI, G. P. KOBINGER: "Successful Treatment of Ebola Virus-Infected Cynomolgus Macaques with Monoclonal Antibodies", SCIENCE TRANSLATIONAL MEDICINE, vol. 4, no. 138, 13 June 2012 (2012-06-13), pages 138ra81 - 138ra81, XP055238416, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.3003876 * |
| XIANGGUO QIU, FERNANDO LISA, MELITO P. LENO, AUDET JONATHAN, FELDMANN HEINZ, KOBINGER GARY, ALIMONTI JUDIE B., JONES STEVEN M.: "Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection", PLOS NEGLECTED TROPICAL DISEASES, PUBLIC LIBRARY OF SCIENCE, US, vol. 6, no. 3, 20 March 2012 (2012-03-20), US , pages e1575, XP055238411, ISSN: 1935-2727, DOI: 10.1371/journal.pntd.0001575 * |
| XIANGGUO QIU; JUDIE B. ALIMONTI; P. LENO MELITO; LISA FERNANDO; UTE STRöHER; STEVEN M. JONES;: "Characterization ofglycoprotein-specific monoclonal antibodies", CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 141, no. 2, 13 August 2011 (2011-08-13), AMSTERDAM, NL , pages 218 - 227, XP028322702, ISSN: 1521-6616, DOI: 10.1016/j.clim.2011.08.008 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12152067B2 (en) | Human antibodies to ebola virus glycoprotein | |
| US11117955B2 (en) | Anti-Zika virus antibodies and methods of use | |
| US10406222B2 (en) | Human antibodies to Middle East Respiratory Syndrome—coronavirus spike protein | |
| HK40127060A (en) | Human antibodies to ebola virus glycoprotein | |
| EA048493B1 (ru) | Применение фармацевтических композиций человеческих антител к гликопротеину вируса эбола | |
| OA18324A (en) | Human antibodies to Ebola virus glycoprotein. | |
| BR122025000707A2 (pt) | Molécula polinucleotídica isolada, vetor, célula isolada, método de produção de um anticorpo ou fragmento de ligação ao antígeno do mesmo, e, conjunto de moléculas polinucleotídicas |